In ongoing discussions with investors and partners, the Company has identified that its current marketplace and valuation do not adequately reflect its scientific progress or long-term potential. A capital raise of the scale required to conduct the planned full-scale patient study is not considered feasible under current conditions.

Strategic rationale for a U.S. listing

The Board of Directors of the Company, following a thorough evaluation of the Company's strategic alternatives, has identified several reasons why a listing of the Company's shares on a U.S. stock exchange could be beneficial for both the Company and its shareholders:

• Access to capital: The U.S. capital market provides greater access to venture capital, particularly for innovative life science companies.
• Valuation potential: A U.S. listing may enable a market valuation that, in the Board's view, more accurately reflects the Company's scientific progress and commercial potential.
• Life Science Hub: The U.S. is an attractive and leading hub for global life science investments, with strong institutional and strategic investor interest.
• Institutional investors and partners: A U.S. listing opens up new opportunities for international institutional investors, as well as new potential investor partners.
• Therapeutic alignment: Interest in innovative anti-inflammatory drugs such as Apta-1 is particularly high in the U.S. clinical and regulatory environment.
• Shareholder interest: A U.S. listing would be designed to strengthen the Company's financing capabilities, support pipeline advancement, and thereby serve the long-term interests of all shareholders.

Next steps

The Company is currently assessing various options for a U.S. listing in order to determine the structure most beneficial for all shareholders. Aptahem has initiated tentative dialogues with advisors, U.S. investors and potential partners to assess how a U.S. listing could be structured in the most beneficial way. Together with its appointed advisor, the Company is currently reviewing the regulatory, legal, and financial implications of different alternatives. Further updates will be communicated as the process develops.

CEO Mikael Lindstam comments:

" Our team has taken Apta-1 through extensive preclinical development and FIM studies with very promising results. We are now ready to take the step towards clinical validation in patients. To make this possible, we need capital that we see can only realistically attract through a broader, international investor base - something that a U.S. listing can make possible. We are humbled by the process, but also determined that this may be the right path for the company and the technology."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

This contains such information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the above contact person for publication on 26 August 2025.

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.